PRESS RELEASE 2000-02-03

Phase II studies against resistant HIV planned for MIV-310

Medivir has decided to proceed with the clinical evaluation of MIV-310 (alovudine, earlier FLT) and will submit an application to perform phase II studies. The clinical trials are expected to start during year 2000.

MIV-310 went through phase I and II clinical trials in AIDS patients during 1991 and 1992. At that time multuresistant HIV had not appeared and since no advantage over zidovudine (AZT) was seen the project was put on ice.

Since then multiresistant HIV has appeared and recent laboratory tests have shown MIV-310 to be very potent against HIV which has become resistant against HIV drugs presently on the market.

Safety data is already available to Medivir from the earlier phase I and II studies. A new phase II study is required to evaluate the effect of MIV-310 in patients with multiresistant HIV.

Professor Bo Öberg will present the new data on MIV-310 and its activity against multiresistant HIV at the now ongoing congress in Stockholm "A Virology Meeting of three Societies". At the same congress Medivir will also present its antihepatitis B substance FLG prodrug which has shown activity against viruses which are resistant against currently available pharmaceuticals.

- We are very pleased to present data for two interesting substances, MIV-310 and FLG prodrug. The is currently an enormous need for drugs which are active against viruses resistant to current therapy.

Huddinge 3 February 2000

Medivir AB (publ)

For further information please contact:

Anna Bernsten, Vice President Business Development and Investor Relations,
Medivir AB, tel +46 8-608 31 05, +46 709-369 069 or E-mail: anna.bernsten@medivir.se
Information about Medivir on internet : www.medivir.se

Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. Medivir has been listed on the Stockholm Stock Exchange since November 1996. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd.